Effects of addition of fenofibrate in high risk patients with combined hyperlipidemia not controlled by pravastatin

被引：0
|
作者：
Ducobu, J.
Farnier, M.
Bryniarshi, L.
机构：
[1] CHU Tivoli, La Louviere, Belgium
[2] Point Med, Dijon, France
[3] Krakov, Pologne, Russia
来源：
DIABETES & METABOLISM | 2007年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [21] Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia
    Lee, Sang-Hak
    Cho, Kyoung-Im
    Kim, Jang-Young
    Ahn, Young Keun
    Rha, Seung-Woon
    Kim, Yong-Jin
    Choi, Yun-Seok
    Choi, Si Wan
    Jeon, Dong Woon
    Min, Pil-Ki
    Choi, Dong-Ju
    Baek, Sang Hong
    Kim, Kwon Sam
    Byun, Young Sup
    Jang, Yangsoo
    ATHEROSCLEROSIS, 2012, 221 (01) : 169 - 175
  • [22] Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia
    Guo, Jinrui
    Meng, Fanbo
    Ma, Ning
    Li, Chunhua
    Ding, Zhenjiang
    Wang, Hong
    Hou, Ruitian
    Qin, Yingjie
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 110 (09): : 1296 - 1301
  • [23] Effects of Pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension
    Su, SF
    Hsiao, CL
    Chu, CW
    Lee, BC
    Lee, TM
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (05): : 514 - 518
  • [24] The long-term treatment of combined hyperlipidemia in CHD patients with a combination of fluvastatin and fenofibrate
    Widimsky, J
    Hulínsky, V
    Balazovjech, I
    Lánská, V
    ATHEROSCLEROSIS, 1999, 144 : 181 - 181
  • [25] Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined Hyperlipidemia and metabolic syndrome
    Vega, GL
    Ma, PTS
    Cater, NB
    Filipchuk, N
    Meguro, S
    Garcia-Garcia, AB
    Grundy, SM
    AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (08): : 956 - 960
  • [26] Effects of atorvastatin and fenofibrate on postprandial lipemia in type 2 diabetic patients with hyperlipidemia
    Iovine, C
    Lilli, S
    Gentile, A
    Patti, L
    Di Marino, L
    Cipriano, P
    Riccardi, G
    Rivellese, AA
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 110 - 110
  • [27] The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia
    Saklamaz, A
    Comlekci, A
    Temiz, A
    Caliskan, S
    Ceylan, C
    Alacacioglu, A
    Yesil, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (05): : 677 - 681
  • [28] BILIARY LIPID SECRETION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND COMBINED HYPERLIPIDEMIA - INFLUENCE OF BEZAFIBRATE AND FENOFIBRATE
    LEISS, O
    MEYERKRAHMER, K
    VONBERGMANN, K
    JOURNAL OF LIPID RESEARCH, 1986, 27 (07) : 713 - 723
  • [29] Assessment of efficacy of fluvastatin and fenofibrate in patients with noninsulin-dependent diabetes with hypercholesterolemia and combined hyperlipidemia
    Kozlov, SG
    Lyakishev, AA
    Tvorogova, MG
    KARDIOLOGIYA, 2000, 40 (05) : 4 - 9
  • [30] Attainment of cholesterol goals with Fenofibrate 160 mg/Pravastatin 40 mg Therapy in Type 2 Diabetic patients with combined hyperlipidemia in primary prevention, not at goal on Simvastatin 20 mg
    Farnier, M.
    Dluzniewski, M.
    Csazar, A.
    Steinmetz, A.
    Retterstol, K.
    EUROPEAN HEART JOURNAL, 2010, 31 : 390 - 390
12345